Risk factors for development and progression of chronic kidney disease: A systematic review and exploratory meta-analysis

Medicine (United States)

Volumn 95, Issue 11, 2016, Pages

  Tsai, Wan Chuan ^a,b   Wu, Hon Yen ^a,b,c   Peng, Yu Sen ^a,c   Ko, Mei Ju ^d,e   Wu, Ming Shiou ^c   Hung, Kuan Yu ^c   Wu, Kwan Dun ^c   Chu, Tzong Shinn ^c   Chien, Kuo Liong ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Department of Internal Medicine ^*  (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT TOOL; DIABETES MELLITUS; DISEASE COURSE; EFFECT SIZE; END STAGE RENAL DISEASE; FEASIBILITY STUDY; FOLLOW UP; HAZARD RATIO; HUMAN; KIDNEY FUNCTION; META ANALYSIS; NEWCASTLE OTTAWA SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; QUALITY CONTROL; RISK FACTOR; SYSTEMATIC REVIEW; DIABETIC NEPHROPATHIES; RENAL INSUFFICIENCY, CHRONIC;

DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84962028695     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003013     Document Type: Article

References (44)

1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375:1296-1309.
2. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet. 2008;371:2173-2182.
3. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008.
4. Wu HY, Hung KY, Tu YK, et al. Comparative effectiveness of antihypertensive drugs in patients with diabetes. J Comp Eff Res. 2014;3:213-215.
5. Iseki K, Iseki C, Kinjo K. C-reactive protein is a predictor for developing proteinuria in a screened cohort. Nephron Clin Pract. 2011;117:c51-56.
6. Chien KL, Lin HJ, Lee BC, et al. A prediction model for the risk of incident chronic kidney disease. Am J Med. 2010;123:836-846e832.
7. Fukuma S, Kurita N, Fukagawa M, et al. Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney Int Suppl. 2013;3:436-441.
8. Wu HY, Huang JW, Peng YS, et al. Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review. Ren Fail. 2013;35:607-614.
9. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(1 suppl 1):S1-S305.
10. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70:1694-1705.
11. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003;14:S65-70.
12. O'Seaghdha CM, Hwang SJ, Bhavsar NA, et al. Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population. Am J Kidney Dis. 2011;57:841-849.
13. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80:1231-1238.
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-266.
15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ nosgen.pdf (accessed January 18, 2016).
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. http:// www.cochrane-handbook.org (accessed January 18, 2016).
17. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-894.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
19. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
20. Evans M, Fryzek JP, Elinder CG, et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis. 2005;46:863-870.
21. Levin A, Djurdjev O, Beaulieu M, et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52: 661-671.
22. Hoefield RA, Kalra PA, Baker P, et al. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010;56:1072-1081.
23. De Nicola L, Chiodini P, Zoccali C, et al. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol. 2011;6:2421-2428.
24. Obi Y, Kimura T, Nagasawa Y, et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol. 2010;5:1558-1565.
25. Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest. 1994;94:1823-1829.
26. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995;25:515-533.
27. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319-329.
28. Jafar TH, Schmid CH, Stark PC, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant. 2003;18: 2047-2053.
29. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. 1996;50:1651-1658.
30. Monti MC, Lonsdale JT, Montomoli C, et al. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes. J Clin Endocrinol Metab. 2007;92:4650-4655.
31. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25:859-864.
32. Ruggenenti P, Gambara V, Perna A, et al. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol. 1998;9:2336-2343.
33. Jacobsen P, Rossing K, Tarnow L, et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl. 1999;71:S101-105.
34. Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314:783-788.
35. Holl RW, Grabert M, Thon A, et al. Urinary excretion of albumin in adolescents with type 1 diabetes: persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care. 1999;22:1555-1560.
36. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in Renal Disease Study. Kidney Int. 1997;51:1908-1919.
37. Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 1998;53:1209-1216.
38. Remuzzi G, Bertani T. Pathophysiology of progressive nephropa-thies. N Engl J Med. 1998;339:1448-1456.
39. Wu HY, Peng YS, Chiang CK, et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis. JAMA Intern Med. 2014;174:1108-1115.
40. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.
41. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79: 1331-1340.
42. Inker LA, Levey AS, Pandya K, et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014;64:74-85.
43. Hayashino Y, Fukuhara S, Akizawa T, et al. Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Res Clin Pract. 2010;90:154-159.
44. Hsu CY, Bates DW, Kuperman GJ, et al. Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis. 2000;36: 272-281.